Slide 1: Q4'24 Earnings Presentation
NASDAQ: HBIO Q4’24 Earnings Presentation Jim Green, Chairman, President & CEO Jennifer Cote, CFO & Treasurer March 12, 2025 1
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward- looking statements may be identified
Slide 3: CEO Summary: Q4'24 Highlights
CEO Summary: Q4’24 Highlights Stay the course, stay lean and remain focused on product commercialization for new revenue streams Income Statement Components ($ in millions except percentages) Q4 2024 Q4 2023 Revenue 24.6 28.2 Gross Margin 14.0 16.3 % of Revenue 57.1% 58.0% Operating Income 0.0 0.3 %
Slide 4: Quarterly Product Revenue by Region
Fx Adjustment Quarterly Product Revenue by Region (in $M) CMT Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 $ 13.10 $ 10.88 $ 11.70 $ 11.81 $ 11.52 Q4 Preliminary; Unaudited Pre-Clinical $ 15.06 $ 13.49 $ 11.43 $ 10.09 $ 13.06 Currency* $ 0.14 $ (0.03) $ 0.07 $ (0.02) Total $ 28.15 $ 24.51 $ 23.10 $ 21.97 $ 24.56 P
Slide 5: Q4'24 Financial Metrics (GAAP except where noted)
Q4’24 Financial Metrics (GAAP except where noted) $ Million except REVENUE ADJUSTED EBITDA* per share data GROSS MARGIN $14.0 $16.3 $3.6 $3.0 EARNINGS (LOSS) PER SHARE CASH FLOW FROM OPERATIONS NET DEBT* GAAP Adjusted* Q4’24 Q4’23 Q4’24 Q4’23 * Non-GAAP measure, reconciliations to GAAP financial mea
Slide 6: FY24 Financial Metrics (GAAP except where noted)
FY24 Financial Metrics (GAAP except where noted) $ Million except REVENUE ADJUSTED EBITDA* GROSS MARGIN per share data $14.6 $54.8 $66.1 $7.2 EARNINGS (LOSS) PER SHARE CASH FLOW FROM OPERATIONS NET DEBT* GAAP Adjusted* FY24 FY23 FY24 FY23 * Non-GAAP measure, reconciliations to GAAP financial measure
Slide 7: New Product Introductions: Focused on Commercialization
New Product Introductions: Focused on Commercialization Extending our Fisher and VWR distribution sales to North America and on plan to expand offerings to include MEA Systems EXPAND TO HIGH GROWTH: EXPAND TO HIGH GROWTH: STRENGTHEN THE BASE: DELIVER > MARKET GROWTH BIO-PRODUCTION IN-VITRO ORGANOID
Slide 8: New Product Introductions: Supports Long Term Growth Targets
New Product Introductions: Supports Long Term Growth Targets Growth Category Product Line 2024 Achievements 2025 Goals • Expanding endpoints including cardiac and neuro • SoHo (Shared Housing) • First shipments for temperature and • Showcasing March Society of Toxicology NextGen Implantable Telemetr
Slide 9: Outlook
Outlook 9
Slide 10: Q1 2025 Outlook
Q1 2025 Outlook Considering the uncertainty around NIH funding and academic research purchasing along with normal Q4 to Q1 seasonality, we expect: ▪ Revenues ranging from $19M to $21M ▪ Gross Margin ranging from 56-58% 10
Slide 11: Reconciliation to GAAP P&L
Reconciliation to GAAP P&L (1) Other operating expenses for the three months ended December 31, 2024 includes $0.2 million of restructuring-related charges. Other operating expenses for the twelve months ended December 31, 2024 includes a $0.5 million commission fee paid in connection with the recei
Slide 12: Confidential & Proprietary Information
Confidential & Proprietary Information 12 12